STRATA Skin Sciences announced that it will add more than twelve new recurring TheraclearX accounts in Mexico by the end of 2025, following its presentation at the 2025 Ibero‑Latin American Congress of Dermatology (TeraCILAD) held November 19‑22. The company highlighted early commercial placements of the TheraclearX acne‑therapy system in the region and noted that dermatologists in Mexico are adopting the device for routine patient treatment plans.
The expansion is enabled by the device’s regulatory clearance from Mexico’s health authority, COFEPRIS, on October 28, 2025, and a partnership with MINO Labs, a Mexican distributor that will facilitate the commercial rollout. The partnership is expected to accelerate market penetration and support the company’s goal of deploying 200 TheraclearX devices by year‑end.
STRATA’s Q3 2025 earnings report revealed a 20% year‑over‑year revenue decline to $6.9 million and a net loss of $1.6 million, driven largely by a 60% drop in equipment revenue. However, global recurring revenue grew 3% year‑over‑year, underscoring the company’s focus on building a resilient subscription model. The Mexico expansion is positioned to strengthen this recurring stream and offset the decline in equipment sales, providing a new source of predictable revenue in a high‑growth market.
Chief Operating Officer Shmuel Gov emphasized that the growing interest in non‑pharmaceutical, device‑based solutions reflects a broader demand for chronic skin‑condition treatments. CEO Dr. Dolev Rafaeli noted that the company’s “challenging international environment” has pressured overall revenue, but the Mexico expansion demonstrates a strategic pivot toward markets where device adoption is accelerating and recurring revenue can be captured.
The expansion comes at a time when STRATA faces headwinds from declining equipment sales and a competitive landscape that pressures pricing. The company’s focus on recurring revenue, supported by the Mexico expansion, signals management’s confidence in long‑term growth and a shift toward higher‑margin, subscription‑based business models. Investors will view the new contracts as a positive tailwind that could help stabilize earnings in future quarters.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.